Tesamorelin should not be used in children with open epiphyses, among whom excess GH and IGF-I may result in linear growth acceleration and excessive growth.
- TRADE NAME: Egrifta (Theratechnologies)
- INDICATIONS: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
- CLASS: Growth hormone-releasing hormone analog
- HALF-LIFE: 26–38 minutes
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cytochrome P450-metabolized drugs
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 01/31/2024
